Baidu
map

糖尿病患者血脂管理中国专家共识(2024版)

2024-04-24 中国循环杂志 发表于上海

本共识旨在传递重要临床进展,指导临床实践,以改善糖尿病患者的心血管结局。

中文标题:

糖尿病患者血脂管理中国专家共识(2024版)

发布机构:

发布日期:

2024-04-24

简要介绍:

糖尿病是动脉粥样硬化性心血管疾病(ASCVD)的重要独立危险因素,血脂异常在糖尿病患者的ASCVD发生和发展中起关键作用。目前我国糖尿病患者中血脂异常患病率高且控制现状不容乐观。因此,为了加强糖尿病患者的血脂管理,中国医师协会内分泌代谢科医师分会和国家心血管病专家委员会心血管代谢医学专业委员会组织专家,根据中国糖尿病患者的血脂管理现状,参考国内外新的循证证据和指南,制定了《糖尿病患者血脂管理中国专家共识(2024版)》。本共识内容涵盖糖尿病患者的血脂谱特点和血脂异常流行病学现状以及糖尿病全人群的ASCVD危险分层和血脂管理流程,首次将低密度脂蛋白胆固醇(LDL-C)与非高密度脂蛋白胆固醇(非HDL-C)均作为糖尿病患者血脂干预的首要靶点,并对糖尿病特殊人群(包括儿童和青少年、≥75岁老年人以及合并慢性肾脏病、代谢相关脂肪性肝病、妊娠的患者)的血脂管理策略进行了推荐。本共识旨在传递重要临床进展,指导临床实践,以改善糖尿病患者的心血管结局。

相关资料下载:
糖尿病患者血脂管理中国专家共识(2024版).pdf
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-11 田沛文 来自山西省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 坐井观天下 来自海南省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 ms5000000231838559 来自湖北省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 慢川 来自浙江省

    学习了

    0

拓展阅读

《糖尿病患者血脂管理中国专家共识(2024版)》 5 大要点解读

本报特邀中南大学湘雅二医院周智广教授团队,对《共识》要点内容进行了梳理解读,以飨读者。

近380万中国人群研究:“坏胆固醇”降到多少更合适?3类人群3个参考值

研究不仅印证了LDL-C与死亡率之间的关联在不同ASCVD风险人群中有所不同,而且提示中国人群中ASCVD风险较高的个体和糖尿病患者可能需要更严格的脂质控制目标。

胡盛寿院士团队研究:达到这个LDL-C最佳水平,或可将死亡风险降至最低!

阜外医院研究表明,不同 ASCVD 风险人群中最低死亡风险对应的 LDL-C 水平不同,提示应采取不同血脂管理策略,ChinaHEART 项目提供数据支持。

血脂化验单没“箭头”代表正常?上海部分医院试点新版化验单

心血管疾病是中国城乡居民第一位死亡原因。动脉粥样硬化是导致心梗、脑梗等动脉粥样硬化性心血管疾病(ASCVD)的主因,而高血脂是动脉粥样硬化斑块形成的重要危险因素。

“坏胆固醇”降低可达85%!最新科学声明:2大策略助力中风患者降脂治疗

《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》于不久前发表,《医学新视点》对其中的相关推荐建议进行了整理。

中国超35%人血脂异常!2024指南:每半年一次降脂药将“坏胆固醇”降低60%……

近年来,中国成人血脂异常患病率一直处于较高水平,2018年调查数据显示其总患病率达到了35.6%,与2015年调查数据相比有所上升。在此背景下,血脂管理刻不容缓。

2015 ACC/AHA 二级预防血脂管理绩效评估指南

美国心脏病学会(ACC,American College of Cardiology) · 2015-12-10

2020 TES临床实践指南:内分泌疾病患者的血脂管理

美国内分泌学会(TES,The Endocrine Society) · 2020-12-01

2022 中国台湾指南:高风险患者的血脂管理—冠状动脉疾病、外周动脉疾病和缺血性卒中(更新版)

中国台湾血脂及动脉硬化学会(Taiwan Society of Lipids & Atherosclerosis) · 2022-04-08

2019年ESC/EAS血脂管理指南要点解读

中国医学科学院北京协和医学院国家心血管病中心阜外医院血脂异常与心血管疾病诊治中心 · 2019-11-20

2020 AACE临床实践指南:内分泌疾病患者的血脂管理

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2020-05-13

Baidu
map
Baidu
map
Baidu
map